Responses
Clinical/translational cancer immunotherapy
Original research
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
Compose a Response to This Article
Other responses
No responses have been published for this article.